Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:12 pm Purchase | 2024-12-31 | 13G | ProQR Therapeutics N.V. PRQR | Van Herk Investments B.V. | 11,461,995 10.900% | 3,291,741 (+40.29%) | Filing History |
| 2025-02-12 09:46 am Purchase | 2024-12-31 | 13G | ProQR Therapeutics N.V. PRQR | Adage Capital Management L.P. | 9,602,280 9.300% | 9,602,280 (New Position) | Filing History |
| 2024-02-14 06:08 am Purchase | 2024-02-09 | 13G | ProQR Therapeutics N.V. PRQR | Van Herk Investments B.V. | 8,170,254 10.100% | 1,024,035 (+14.33%) | Filing History |
| 2024-02-09 06:37 am Purchase | 2023-12-31 | 13G | ProQR Therapeutics N.V. PRQR | Van Herk Investments B.V. | 7,146,219 8.800% | 2,865,354 (+66.93%) | Filing History |
| 2023-09-14 5:20 pm Purchase | 2023-09-11 | 13G | ProQR Therapeutics N.V. PRQR | Van Herk Investments B.V. | 4,280,865 5.300% | 4,280,865 (New Position) | Filing History |
| 2023-02-14 10:13 am Sale | 2022-12-31 | 13G | ProQR Therapeutics N.V. PRQR | RTW Investments, LP | 0 0.000% | -7,027,725 (Position Closed) | Filing History |
| 2023-02-09 5:00 pm Purchase | 2022-12-31 | 13G | ProQR Therapeutics N.V. PRQR | Stichting Aescap Life Sciences | 5,406,159 7.600% | 578,787 (+11.99%) | Filing History |
| 2023-02-09 12:31 pm Sale | 2023-02-09 | 13G | ProQR Therapeutics N.V. PRQR | FMR LLC | 0 0.000% | -4,462,438 (Position Closed) | Filing History |
| 2023-02-09 11:50 am Sale | 2022-12-31 | 13G | ProQR Therapeutics N.V. PRQR | ADAGE CAPITAL PARTNERS GP L.L.C. | 3,628,467 4.490% | -1,086,685 (-23.05%) | Filing History |
| 2023-02-07 6:11 pm Sale | 2022-12-30 | 13G | ProQR Therapeutics N.V. PRQR | GOLDMAN SACHS GROUP INC GS | 9,164 0.000% | -3,964,486 (-99.77%) | Filing History |
| 2022-12-23 4:39 pm Purchase | 2022-12-21 | 13G | ProQR Therapeutics N.V. PRQR | ELI LILLY & Co LLY | 13,371,562 16.600% | 9,381,586 (+235.13%) | Filing History |
| 2022-05-09 3:31 pm Sale | 2022-04-29 | 13G | ProQR Therapeutics N.V. PRQR | WELLINGTON MANAGEMENT GROUP LLP | 0 0.000% | -4,017,760 (Position Closed) | Filing History |
| 2022-02-14 08:10 am Purchase | 2021-12-31 | 13G | ProQR Therapeutics N.V. PRQR | RTW Investments, LP | 7,027,725 9.900% | 1,939,232 (+38.11%) | Filing History |
| 2022-02-10 10:51 am Purchase | 2021-12-31 | 13G | ProQR Therapeutics N.V. PRQR | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,715,152 6.630% | 165,090 (+3.63%) | Filing History |
| 2022-02-09 10:24 am Purchase | 2022-02-08 | 13G | ProQR Therapeutics N.V. PRQR | FMR LLC | 4,462,438 6.271% | 4,224,522 (+1775.64%) | Filing History |
| 2022-02-07 1:57 pm Purchase | 2021-12-31 | 13G | ProQR Therapeutics N.V. PRQR | GOLDMAN SACHS GROUP INC GS | 3,973,650 5.600% | 467,286 (+13.33%) | Filing History |
| 2022-02-04 4:58 pm Purchase | 2021-12-31 | 13G | ProQR Therapeutics N.V. PRQR | Stichting Aescap Life Sciences | 4,827,372 6.800% | 1,623,176 (+50.66%) | Filing History |
| 2022-02-04 09:12 am Purchase | 2021-12-31 | 13G | ProQR Therapeutics N.V. PRQR | WELLINGTON MANAGEMENT GROUP LLP | 4,017,760 5.650% | 561,995 (+16.26%) | Filing History |
| 2021-09-10 1:03 pm Purchase | 2021-09-03 | 13G | ProQR Therapeutics N.V. PRQR | ELI LILLY & Co LLY | 3,989,976 5.600% | 3,989,976 (New Position) | Filing History |
| 2021-04-05 6:26 pm Purchase | 2021-02-01 | 13G | ProQR Therapeutics N.V. PRQR | RTW Investments, LP | 5,088,493 10.100% | 78,725 (+1.57%) | Filing History |